MedPath

A randomised placebo controlled crossover trial to evaluate the effects of intrajejunal taurocholic acid on gastrointestinal hormone secretion and glycaemia in response to intrajejunal glucose infusion in healthy humans for the future design of treatments for type 2 diabetes mellitus

Phase 1
Completed
Conditions
Designing future treatments for type 2 diabetes mellitus
Metabolic and Endocrine - Diabetes
Registration Number
ACTRN12612001213831
Lead Sponsor
Royal Adelaide Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
14
Inclusion Criteria

Healthy subjects; Body mass index (BMI) 19 - 30 kg/m2; Haemoglobin > 135 g/

Exclusion Criteria

Medications affecting gut function; Alcohol intake >20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath